In a significant medical feat, Indian scientists have developed the first-in-human gene therapy using lentiviral vectors for ...
Haemophilia is a severe bleeding disorder caused by the deficiency of clotting Factor VIII, leading to spontaneous internal ...
Current treatments require frequent Factor VIII replacement therapy, which faces challenges such as high costs, venous access ...
Breakthrough in Delivering Chimeric Bait Receptors to Immune Cells Accelerates Development LONDON, UK / ACCESSWIRE / December ...
Rocket Pharmaceuticals' gene therapy treatments for rare diseases are promising. See why I think high cash burn and potential ...
internal ribosome entry siteS or 2A elements can be used to link various transgenes in bi- or multi-cistronic retroviral vectors. Lentiviral self-inactivating vectors are the retroviral vectors ...
Vyriad’s lentivirus vectors target T cells within a patient’s body and deliver genes coding for chimeric antigen receptors. Once the T cells decipher those genetic instructions, they are ...
ESO-T01 is the first in vivo BCMA CAR-T candidate to reach the clinical stageEarly clinical data are expected in second half of ...
In the groundbreaking study the researchers observed an annualised zero bleeding rate in all the five subjects enrolled with ...
India has successfully conducted its first in-human gene therapy for hemophilia A, with patients experiencing no bleeding ...
The FDA notification came seven weeks after the New England Journal of Medicine (NEJM) published a report that seven of 67 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback